Medacta : 2021 Full Year Unaudited Top-Line Figures Presentation

FY 2021 PRELIMINARY UNAUDITED TOP-LINE FIGURES

20 January 2022

DISCLAIMER

This presentation (the "Presentation") has been prepared by Medacta Group SA ("Medacta" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on our website at https://www.medacta.com/EN/investors.

Unaudited Financial Results

The financial information contained in this Presentation is unaudited.

Forward-looking information

This Presentation has been prepared by Medacta and may include forward-looking information and statements concerning the outlook for our business. These statements are based on current expectations, estimates and projections about the factors that may affect our future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as "expects", "believes", "estimates", "targets", "plans", "outlook" or similar expressions.

There are numerous risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from the forward- looking information and statements made in this Presentation. Currently, it is very difficult to provide a meaningful prediction on how governments will act in response to the ongoing outbreak of a novel coronavirus disease (COVID-19), how it will affect the Medacta's operations and how long such measures will remain in place. The Covid- 19 outbreak has caused, and may continue to cause, economic instability and a significant decrease of total economic output in the affected areas and globally. The impact of the Covid-19 outbreak on the general economic environment in the markets in which Medacta operates remain uncertain and could be significant. In addition, other important factors that could cause such differences include: changes in the global economic conditions and the economic conditions of the regions and markets in which the Group operates; changes in healthcare regulations (in particular with regard to medical devices); the development of our customer base; the competitive environment in which the Group operates; manufacturing or logistics disruptions; the impact of fluctuations in foreign exchange rates; and such other factors as may be discussed from time to time. Although we believe that our expectations reflected in any such forward-looking statement are based upon reasonable assumptions, we can give no assurance that those expectations will be achieved.

Alternative Performance Measures

This Presentation may contain information regarding alternative performance measures. Definitions of these measures and reconciliations between such measures and their IFRS counterparts if not defined in the Presentation may be found on the financial reports available on our website at https://www.medacta.com/EN/investors.

THIS PRESENTATION IS NOT AN INVITATION TO PURCHASE SECURITIES OF MEDACTA OR THE GROUP.

2

FRANCESCO SICCARDI	CORRADO FARSETTA
Chief Executive Officer	Chief Financial Officer

FY 2021 Preliminary Unaudited Top-Line Figures

HIGHLIGHTS

FY 2021 Revenue1

Euro 363.1 million

Positive revenue contribution from all business lines and geographies

Revenue Growth vs FY20

21.4% at constant currency

20.0% reported

Significant carry-over and customer acquisition, in addition to normalization of surgical activities, which were limited by further pandemic restrictions throughout the year

Innovation

50+ new products registered in 1H before the new European Medical Devices Regulation fully entered into force

Medical Education

New customer acquisition thanks to Medical Educations back to normal level with significant increase compared to 2019

Group Hirings

150+ new jobs added, including significant salesforce expansion

Notes:

1. Unaudited figures

4

DEPLOYMENT OF THE NEXTAR™ AR SURGICAL PLATFORM

• NextAR, our Augmented Reality Surgical Platform, empowers the surgeon's vision with real-timesurgical guidance superimposed onto the operative field to make data-drivendecision-making
• All NextAR Platform applications for knee, shoulder and spine surgery are CE marked and FDA cleared. Currently all the applications are in Limited Market Release to build Reference Centre Network
• An innovative solution designed to improve accuracy and efficiency in surgical procedures, with low upfront capital investment and cost per case compared to other technologies
• NextAR can be the optimal solution worldwide, and particularly for U.S. Ambulatory Surgery Centers ("ASCs")

5